Introduction {#s0010}
============

Mucosal immunological defense in the middle ear utilizes a number of mechanisms, including physicochemical barriers of mucus and the mucosal epithelial cells and innate immune responses such as inflammation, cellular infiltration, effusion, and antimicrobial protein and peptide secretions, in addition to adaptive host immune responses.

Immunology of the tubotympanum has been studied primarily during infection states. Development of mucosal immune responses to antigens continues through infancy and early childhood (Chapter 11) ([@bib20], [@bib113]), at a time when eustachian tube morphology increases the child's risk of otopathogen access to the middle ear and development of otitis media (OM) ([@bib86], [@bib9]). Furthermore, infants and children experiencing gastroesophageal reflux may have increased risk of OM due to ongoing upregulation of mucosal responses by the presence of pepsin within the eustachian tube and middle ear. Pepsin is reported to stimulate middle ear inflammation and increase the risk of chronic otitis media with effusion (COME) ([@bib108]). Infancy and early childhood are the periods of highest incidence of OM, with the peak incidence of acute otitis media (AOM) occurring in the first 6 months of life and the recurrence of OM being common up to 7 years of age ([@bib113]).

This chapter describes the morphology of immunological tissue within the tubotympanum, the characteristics of local immune responses to common otopathogens, and regulation of the mucosal immune responses in the middle ear. Throughout this chapter, discussion is informed by the immune responses observed during OM from animal models and human clinical studies (for review see [@bib110]).

Mucosal Immune Characteristics of the Tubotympanum {#s0015}
==================================================

Anatomically, the tubotympanum comprises the middle ear and the eustachian tube. The middle ear is a unique cavity and is normally considered a "sterile" environment ([@bib72]) despite its proximity to the nasopharynx, a region of extensive antigen exposure in healthy individuals ([@bib88]). The middle ear is lined with a simple mucosal membrane with typically few immunocytes present ([@bib87], [@bib56]), and the eustachian tube forms a direct conduit between the middle ear and nasopharynx, increasing the opportunity for microbial and allergenic antigen exposure.

Mucosal Tissue Organization of the Middle Ear {#s0020}
---------------------------------------------

Structurally, the human middle ear cavity may be considered anatomically partitioned at the level of the tympanic membrane into an attic or epitympanic region above the membrane, then descending through the mesotympanic region adjacent to the tympanic membrane to the hypotympanic or anterior inferior region of the middle ear cavity ([@bib3], [@bib9], [@bib87]). See [Figure 1](#f0010){ref-type="fig"} .Figure 1Diagrammatic representation of the middle ear showing the distribution of the ciliated cells within the epitympanum, mesotympanum, and hypotympanum, which form the mucociliary transport pathways from the middle ear to the eustachian tube.Adapted from [@bib87] and [@bib88].

The middle ear cavity is lined with a thin mucosal membrane that covers all structures, such as the ossicles, and is continuous with the mucosal membrane in the mastoid antrum, eustachian tube, and nasopharynx ([@bib86], [@bib87]). The mucosal epithelium within the epitympanic region is composed primarily of squamous epithelia with islands of ciliated columnar cells. These islands form a functional mucociliary pathway from the mastoid antrum in the epitympanum, through the mesotympanum, toward the eustachian tube. Similarly, the squamous epithelium of the mesotympanum has two paths of ciliated columnar cells, one continuing the path from the epitympanum and mastoid antrum and the other connecting the tympanic membrane through the hypotympanum to the eustachian tube.

In the healthy middle ear, the mucosal surface of the mesotympanum is composed equally of squamous and ciliated columnar cells. The number of ciliated columnar epithelial cells in the mucosal lining progressively increases toward the eustachian tube to constitute about 80% of the cells adjacent to the eustachian tube entrance. These histomorphological changes evidence the progressive transformation from flat, nonsecretory squamous epithelium to respiratory epithelium that is pseudostratified, ciliated columnar cells just proximal to the eustachian tube entrance ([@bib9], [@bib86], [@bib87], [@bib3]). The changing cellular architecture of the middle ear cavity facilitates function of an organized mucociliary transportation system from primarily the epitympanum and hypotympanum to the eustachian tube, as illustrated in [Figure 1](#f0010){ref-type="fig"}.

Within the eustachian tube, respiratory epithelial cells are tightly interconnected and utilize occludin and various members of the claudin family at tight junctions and E-cadherin at adherin junctions to optimize physical resilience of the membrane ([@bib155], [@bib169]). These epithelial cells are ciliated and, in addition to goblet cells, also secrete mucus ([@bib87]). Within the middle ear and eustachian tube, secretory glands secrete two types of mucus: mucoid and serous ([@bib87]). Serous fluid is less viscous and is considered the origin of the periciliary fluid that aids mucociliary clearance of these regions. (For review, see [@bib87].) Mucoid secretion also provides lubrication of the epithelial cell boundary of the mucosal membrane ([@bib156]) and together, the glandular and mucosal epithelial cells in these regions are the front line for secretion of molecules of innate immunity ([@bib86], [@bib87], [@bib88]). For example, in children, mucoid effusions from chronically infected middle ears contain higher concentrations of lysozyme, an antimicrobial enzyme ([@bib94]) that was localized to middle ear epithelial goblet cells ([@bib89]) and has been demonstrated to reduce susceptibility to OM in the murine model ([@bib135]).

Efficiency of middle ear mucociliary clearance in infants and young children is impaired by the shorter, wider, more horizontal morphology of the eustachian tube, which increases the opportunity for antigen exposure or pathogen colonization while reducing the opportunity for mucosal immune responses, compared to the adult morphology ([@bib9]). To assist mucociliary clearance of the middle ear, the epithelium of the epitympanum, although primarily squamous, is well vascularized and performs a gas exchange role with the mastoid and middle ear cavities. Intermittent opening of the eustachian tube, during swallowing and yawning, in conjunction with the mastoid antrum gas pressurization, improves clearance of secretions from the middle ear into the nasopharynx ([@bib3], [@bib86], [@bib9], [@bib99], [@bib87]).

Overall, healthy eustachian tube functions include protection from microbial colonization by remaining predominantly closed, ventilating to regulate air pressure, and using gas-assisted mucociliary activity to improve clearance of secretions from the middle ear and eustachian tube. Obstruction of the eustachian tube by inflammation or impaired mucociliary clearance contributes to increased susceptibility to middle ear infection ([@bib111]). Ultimately, the relative sterility of the middle ear is maintained by continuous mucociliary clearance of the middle ear cavity in combination with host innate and adaptive immune responses ([@bib88]).

Immunocompetent Cells in the Middle Ear Mucosa {#s0025}
----------------------------------------------

Healthy middle ear mucosa is characterized by a simple, thin membrane with typically few immunocompetent cells, as observed in both animal models ([@bib59], [@bib58], [@bib56]) and the human middle ear ([@bib147]). Mast cells and macrophages are the most commonly observed immunocompetent cell types in non-inflamed tissue, with mast cells predominant in healthy middle ears. Mast cells are preferentially distributed in the well-vascularized mucosa or ciliated mucosal epithelial layer of the tubotympanum rather than within the subepithelial layer ([@bib117], [@bib161]). Immunocompetent cell numbers progressively fall as the healthy middle ear is approached from the nasopharynx via the eustachian tube ([@bib162], [@bib161]). Electron microscopic examination of the human tympanic membrane reported non-epithelial cells within the basal epidermis ([@bib168]) that have been subsequently identified as dendritic cells (DC) ([@bib34]). The presence of these antigen presenting cells (APC) within the normal tympanic membrane, albeit sourced from cadaveric specimens, suggests a mechanism for local initiation of a primary immune response. DC and upregulation of cytokine secretion are recognized as elements of the local immunological response of the tympanic membrane to chronic OM and perforation ([@bib19]).

Antigen sampling via mucosa-associated lymphoid tissue (MALT) is not typically observed in the healthy middle ear in either animal models or healthy human ears. A single report of post mortem tissue suggests that MALT is present in the eustachian tube and middle ear of children; however, this study did not examine the clinical history of the subjects and OM was determined by the presence of effusion or cellular infiltration at post mortem ([@bib101]). In the rat, the frequency of MALT observed in the eustachian tube reduced as the middle ear was approached and suggests an effector rather than inductive immune role for the middle ear epithelium.

Otopathogens {#s0030}
============

Viral Otopathogens {#s0035}
------------------

Immune responses within the middle ear and eustachian tube are frequently stimulated during upper respiratory tract infections (URI), with innate inflammatory responses to infection contributing to the development of OM in some children ([@bib98]). Viral infection of the upper respiratory tract mucosae, reported in prospective human studies, often precedes and predisposes the middle ear cavity to development of OM ([@bib98]). During one 12-month prospective study, 97% of children aged 6 months to 3 years experienced one or more URI per year, with approximately 10% of children less than 3 years of age experiencing 10 or more infections. AOM was identified in 61% of children experiencing a URI while otitis media with effusion (OME) was observed in 25% of children, with child age being the strongest predictor ([@bib15]). It is not uncommon for children to experience six to eight URI per year ([@bib52]), and approximately 70% of children with a diagnosis of OM have symptoms of a URI. Furthermore, approximately 77% of these children have a virus detected in their nasal secretions ([@bib98], [@bib164]). Adenovirus, respiratory syncytial virus (RSV), influenza A and influenza B virus, parainfluenza virus, coronavirus, enterovirus, and rhinoviruses are commonly associated with OM ([@bib50], [@bib1]).

The number and frequency of viral URI experienced by young children increases the risk and opportunity for ascension via the eustachian tube to infect the middle ear. Although viruses are a commonly detected microbe within the middle ear fluid (MEF) from children with OM, there is recent debate as to whether viral presence equates to OM pathogenesis ([@bib16]). Viruses have been detected in 70% of MEF samples from children with AOM and viral detection alone was observed in only 4% of cases, with 66% of children exhibiting concurrent viral and bacterial infections. Only 26% of the AOM cases exhibited bacterial infection alone ([@bib124]); however, viral infection of the upper airways does have a critical role in the pathogenesis of bacterial OM. A number of studies using combined viral and bacterial otopathogens in the chinchilla model have been recently reviewed ([@bib6]) and confirm that a highly specific interrelationship exists between a respiratory tract viral infection and the bacteria associated with OM as recognized in children ([@bib49], [@bib15]). This relationship varies depending upon the otopathogens involved; for example, in *Moraxella catarrhalis*-induced OM, more than one viral or bacterial co-pathogen may be necessary for OM establishment. Viral/bacterial partnership (interrelationship) facilitates the transfer of nasopharyngeal commensal bacteria into the middle ear via the eustachian tube and increases the risk and severity of bacterial OM infection ([@bib39]). A review on the bacterial and viral interactions on the development of AOM has been recently published ([@bib99]).

Clinically, concurrent viral and bacterial infection of the middle ear results in significant worsening of the clinical course of OM in animal models ([@bib40]) and children compared to virus or bacterial infection alone. For children, increased detection of both virus and bacteria within the MEF was observed in cases of antibacterial failure after 2--4 days of antibiotic administration ([@bib13]). Viral presence within the middle ear can also reduce antibiotic penetration from the serum into MEF ([@bib10]).

Investigation of the immunological responses of the middle ear and their immunoregulation has utilized both acute and chronic OM pathogenesis models using a variety of animal models including, mice, rats, chinchillas, gerbils, monkeys, and guinea pigs and a range of differing modes of pathogen introduction. A recently published modified methodology ([@bib145]) that permits noninvasive, pressurized administration of otopathogens may provide further insight into OM, particularly otopathogen ascension via the eustachian tube from the nasopharynx.

Immunological responses of the middle ear to viral infection may increase the risk of OM development in a number of ways, including enhancing bacterial adherence to epithelial cells ([@bib5]), which is recognized to optimize establishment of a superinfection ([@bib129]). Upper respiratory tract viruses also stimulate increased expression of eukaryotic receptors such as intercellular adhesion molecule 1, carcinoembryonic antigen-related cell adhesion molecule 1, and platelet-activating factor receptor on the mucosal or host cell surface ([@bib43]). Bacteria use these surface receptors as adherence sites and to alter rates of mucus secretion. Viral infection also stimulates innate mucosal immune responses, including inflammation and mucosal membrane thickening and increased mucus secretion by goblet cells, leading to reduced middle ear pressurization ([@bib41]). These local immune responses in the middle ear and eustachian tube have been clearly associated with enhanced susceptibility to OM in the chinchilla model and have been recently reviewed ([@bib6]).

Middle ear inflammation after viral exposure can increase the rate of mucus secretion ([@bib17]) while altering fluid viscosity through upregulation of gel-like mucin secretion. Mucosal epithelial cell synthesis of antimicrobial peptides within the mucus can be impaired by viral infection ([@bib105]), and changes to fluid and ion transport within and through the epithelial cell membrane increases the formation of an edematous mucosal lining and effusion to the middle ear ([@bib95]). Furthermore, reduction of the number and activity of epithelial cell cilia within the eustachian tube by influenza A virus has been demonstrated to reduce the opportunity for neutralizing or clearing otopathogens from the middle ear in the chinchilla model ([@bib118]).

Clearly, viral infection results in interruption or dysregulation of normal inflammatory responses of the mucosa within the eustachian tube and middle ear and permits transit of commensal nasopharyngeal bacteria to the middle ear. Subsequent inability to open the eustachian tube provides minimal opportunity for mucociliary clearance to the nasopharynx and enhances mucosal tissue damage through generation of pressure differential and local superinfection within the middle ear.

Bacterial Otopathogens {#s0040}
----------------------

*Streptococcus pneumoniae*, non-typeable *Haemophilus influenzae* (NTHi), and *M. catarrhalis* are normal commensal flora and the most common bacterial microbes detected in MEF from children with AOM ([@bib124]). Group A *Streptococcus* is also reported as an otopathogen ([@bib131]) and *Alloiococcus otiditis* is reported as a significant otopathogen in some population groups ([@bib4]). Mucosal immune responses within the middle ear and eustachian tube may be overwhelmed by the extent of early bacterial colonization and result in unresolved inflammation within the middle ear. For example, the nasopharyngeal carriage rate for NTHi is higher in children with OME compared to healthy children. Children who experience dense bacterial colonization of the nasopharynx early in life are at significantly increased risk of early OM development and more severe disease, including tympanic membrane perforation, and are at very high risk of suppurative complications of OM ([@bib75], [@bib141]). Effective mucosal immune responses within the middle ear may reduce the impact of bacterial load and/or virulence of the otopathogen. For example, single gene deletion of *slrA* (streptococcal lipoprotein rotamase A) or in combination with *ppmA* gene (putative proteinase maturation protein A) significantly reduced bacterial load and virulence in the nasopharynx and middle ear in a murine experimental AOM model ([@bib145]). The additive effects of deletion of these genes on bacterial colonization and virulence provides further challenge for vaccine development.

The effectiveness of the endogenous mucosal immune responses to AOM, for the children of developed countries at "low risk" of severe OM (i.e., low rates of suppurative complications of OM) is indicated by the high rate of self-resolving OM episodes (80%) ([@bib42]), in turn implying the success of the host mucosal immune responses. For healthy children, middle ear effusion normally resolves within 7 days in 40% of cases, and in 75--90% of cases resolution occurs within 4 weeks ([@bib98]).

Failure of the middle ear infection to self-resolve can result in ongoing persistence of bacterial OM, as either COME or recurrent AOM. Persistent bacterial infection of the adenoids has been the focus of recent microbial studies that demonstrated that *S. pneumoniae*, NTHi, and *M. catarrhalis* can invade and survive within adenoidal cells ([@bib33]). Furthermore, intracellular localization of bacteria within the middle ear mucosal cells has now been confirmed and the bacterial species subsequently identified ([@bib18], [@bib152]). Multi-species bacterial biofilms containing these species have been visualized on the middle ear mucosa and characterized using confocal microscopy. The presence of multiple bacterial species, within the same middle ear mucosal samples, could provide additional protection to each microbe, protecting them from host innate and acquired immune defenses ([@bib2]). Biofilm formation is known to significantly increase bacterial protection from antibiotic treatment ([@bib138]) and the host immune system responses.

Biofilm formation has also been observed in both the nasopharynx and middle ear in the chinchilla model after initial intranasal inoculation with influenza A followed by *S. pneumoniae* a week later ([@bib55]). Inoculation with a variety of bacterial species, in combination with prior viral infection, increases the incidence and severity of OM (in a murine model) ([@bib71]). Biofilm formation occurs rapidly and the presence of bacteria, not successfully cleared by local or systemic immune responses or antibiotic therapy, poses a challenge for vaccine efficacy. The presence of multiple otopathogens within biofilms also increases the rate of horizontal gene transfer between microbes ([@bib97]), which may further increase the challenge for the host mucosal immune response and targeting of successful vaccine development for OM.

Importantly, bacterial OM, including biofilm formation, is most frequently the result of infection by commensal bacteria. Commensal microbes are well adapted to minimize recognition by the host's immune system through molecular mimicry or modulation of host cell innate immune regulation. Recent evidence shows that existing biofilms can be eradicated, in vitro, using an antibody directed against PilA, suggesting that it is possible to develop vaccine strategies that may both prevent and treat OM ([@bib112]) through activation of the host immune system.

Immunoregulation in the Middle Ear {#s0045}
==================================

Mucosal responses to bacterial and viral colonization within the eustachian tube and middle ear include a rapid inflammatory response that effectively seals the eustachian tube. The resultant reduced pressurization of the middle ear causes extravasation of fluid into the middle ear chamber. Together, trapped antigens and otopathogens activate recruitment of immunocompetent cells and then stimulate local antibody secretion, providing evidence that the middle ear is an active effector site.

Over the longer term, mucosal immune responses within the middle ear, as demonstrated by OM, induce pathogenic changes within the tubotympanum mucosa. These changes include increased numbers of mucous glands, goblet cells, and lymphoid follicles containing germinal centers. The thickened mucosa also exhibits increased mucus secretion arising from the mucosal hyperplasia within the eustachian tube ([@bib101]). Within the middle ear, persistent or COME induces increased epithelial thickness and converts the flattened epithelial cells to secretory ciliated pseudostratified columnar cells with significant basal cell hyperplasia ([@bib3], [@bib153]).

Pathogen Recognition {#s0050}
--------------------

Innate host defenses recognize invading pathogens by activation of one or multiple microbial pattern recognition receptors (PRRs) located in the extracellular, membranous, and cytoplasmic compartments of the middle ear epithelium ([@bib85], [@bib79]). PRRs aid the host in discriminating "self" from "non-self" and these receptors may be located at the cell surface, such as transforming growth factor β (TGF-β), or traversing the cell membrane as transmembranous proteins, such as Toll-like receptors (TLR) and C-type lectin receptors. Receptors located within the cytosol include nucleotide-binding oligomerization domain (NOD)-like receptors NOD-1 and NOD-2 and retinoic acid-inducible gene (RIG)-1-like receptors ([@bib79]). Furthermore, bacterial and other non-self DNA may also be detected by PRRs such as TLR9, located on endosomes within the cytoplasm of the epithelial cell, or other cytosolic PRRs such as DNA-dependent activator of IFN regulatory factor (DAI), RNA polymerase III (Pol-III), and absent in melanoma 2 (AIM2) receptors ([@bib84]).

Regardless of their cellular or subcellular location within the middle ear or eustachian tube epithelia, PRRs recognize conserved molecular signatures produced by the pathogens, defined as pathogen-associated molecular patterns (PAMPs), which, in turn, facilitate upregulation of the host immune response. Each pathogen may produce a variety of PAMP molecules including proteins, lipoproteins, lipids, and nucleic acids and thus may activate multiple signaling pathways. A recent study reported upregulated expression of genes involved with non-self DNA sensing via the TLR9, DAI, Pol-III, and AIM2 receptors in the middle ear mucosa of mice following NTHi infection and confirmed their role in bacterial DNA recognition of NTHi induction of OM in this model ([@bib82]). These multiple parallel pathways for DNA signaling during the early innate immune responses to pathogens within the middle ear indicates potential synergistic and/or redundant activation mechanisms to the same pathogen via stimulation via a number of PRRs. Furthermore, as evidenced by microarray analyses, NTHi and *S. pneumoniae* can activate upregulation of the TGF-β signaling pathway overall, despite individual genes being up- or downregulated at the time of study ([@bib80]).

Intracellular Signaling in the Middle Ear {#s0055}
-----------------------------------------

Ultimately, PAMP activation of PRRs induces complex signaling cascades that regulate the local innate immune response within the tissue and can then stimulate both local and systemic adaptive immune responses. Immunoregulatory mucosal immune responses may include alteration of the secretion and timing of various cytokines, interferons, and chemokines from cells located within and recruited to the mucosal epithelium. Cross-talk between these molecules may optimize activation of innate immune responses such as inflammation, but also facilitates attenuation of signaling to minimize the risk of local tissue damage. Evidence of the complexity of TLR-induced signaling in response to NTHi-induced OM in the mouse is explored in a 2011 review ([@bib85]). Middle ear immune responses to bacterial infection are mediated through a variety of receptors and pathways, including TLR-dependent and TLR-independent pathways (NOD-like receptors, RIG-1 receptors, and other cytosolic PRRs), with TLR-dependent pathways the best described.

Increasingly, OM is recognized as a polymicrobial disease and PRRs such as TLR2 and TLR4 can respond to multiple otopathogens, including NTHi and *S. pneumoniae*, to activate innate immune responses, including inflammation of the middle ear mucosa ([@bib154], [@bib73]). For example, multiple otopathogens activate multiple inflammatory inducers through simultaneous activation of nuclear factor kappa beta (NF-κB). This synergistic activation of inflammation inducers occurs through multiple intracellular signaling pathways ([@bib73]) and is indicative of involvement of multiple PRRs in middle ear mucosal responses to infection by common otopathogens.

TLRs are among the best-characterized PRRs within the upper respiratory tract and middle ear, and are located within a variety of cell types including macrophages, mast cells, and DC, as well as the mucosal epithelial cells. TLR receptors in the middle ear mucosa can respond to a number of NTHi PAMP ligands, including peptidoglycans or peptidoglycan-associated proteins such as outer membrane protein P6 and lipooligosaccharide (LOS). These ligands activate both TLR2 and TLR4 receptors ([@bib12], [@bib136], [@bib26]) and are components of bacterial cell membranes, leading to interest in their use as prospective vaccine targets.

A significant body of research has been undertaken using a variety of animal models to explore middle ear immune responses and signaling pathways in NTHi-induced OM. In brief, NTHi activates both TLR2 and TLR4 receptors that recruit and activate TLR adaptor molecules, myeloid differentiation primary response gene 88 (MyD88), and cytoplasmic Toll/interleukin-1 receptor (TIR) domain-containing adaptor-inducing IFN-β (TRIF), respectively. NTHi stimulation of NOD-2 receptors in the cytoplasm can also activate the MyD88-dependent pathway used by all the TLRs (except TLR3), resulting in proinflammatory cytokine production via activation of NF-κB and/or mitogen-activated protein kinase (MAPK) and/or Jun N-terminal protein kinase (JNK). In contrast, TLR4 activation of the TRIF pathway stimulates type 1 interferon and tumor necrosis factor (TNF) production through IFN regulatory factor 3 and acts to delay expression of other inflammatory cytokines. Recently, host cell recognition of *M. catarrhalis* has also been reported to use multiple TLR receptors, including TLR2, TLR4, and TLR9, in addition to the membrane-bound CD14-TLR4 complex. Activation of these receptors results in subsequent activation of both MyD88- and TRIF-dependent pathways within the host innate immune responses. MAPK activation leads to upregulation of TNFα secretion and, together with IL-6, these proinflammatory cytokines are necessary to reduce bacterial loads in TLR4 mutant C3H/HeJ mice ([@bib48]). Different otopathogens may upregulate host inflammatory responses via similar PRRs and signaling pathways, although extensive investigation of NTHi infection demonstrates that a number of different signaling pathways may cooperatively activate host immune responses, as illustrated in [Figure 2](#f0015){ref-type="fig"} . NTHi infection also activates the TGF-β signaling pathway through transmembrane receptors and stimulates phosphorylation of Mothers against decapentaplegic homolog 2 (SMAD2/3) protein, which relocates the SMAD/2/3/4 complex to the nucleus. The SMAD/2/3/4 complex, together with transcription factor, triggers expression of genes involved with extracellular matrix formation, which is an important regulator of tissue remodeling within the middle ear during OM ([@bib80]). Viral otopathogens are detected via a variety of PRRs, for example, single-stranded RNA of influenzavirus stimulates TLR7 (mouse) and TLR8 (human) PRRs within the endosome. Furthermore, genomic RNA can be detected in the cytoplasm by RIG-1, which signals, via IRF3/7 and NF-κB transcription factors, upregulation of inflammatory cytokines and type 1 interferons ([@bib151]). NACHT domain, leucine-rich-repeat and PYD-containing protein 3 (NLRP3) inflammasomes have a role in detection of the M2 protein of influenzavirus and then activate caspase-1, facilitating production of proinflammatory cytokines IL-1β, IL-18, and IL-33 ([@bib57]).Figure 2Intracellular signaling pathways utilized by middle ear mucosa in response to stimulation by non-typeable *Haemophilus influenzae* (NTHi).Pattern recognition receptors (PRR) detect conserved molecular signatures of invading microbes and facilitate activation of synthesis and secretion of downstream cytokine cascades. This figure schematically represents the signaling pathways activated by NTHi both at the cell membrane and within the cell cytoplasm of the middle ear mucosal cells. The information portrayed was extracted from published reports of experiments utilizing middle ear cell lines and middle ear epithelium and mucosa from animal models and human biopsy material. Transmembrane TLR receptors 1, 2, and 4--10 predominate at the cell surface and their activation results in translocation of NF-κB to the nucleus and upregulation of type II interferons and a range of proinflammatory and antimicrobial molecules. TLR3 utilizes an MYD88-independent pathway via TRIF and IRF3 to upregulate type I interferons. In addition, stimulation of TLR3 and 4 may also activate a delayed response (dotted lines) through TAK1, then the JNK p38MAPK pathway or NF-κB to stimulate type II interferons and proinflammatory molecule production. TGF-β activates SMAD 3 and SMAD 4, ultimately upregulating NF-κB; however, the mechanism for this pathway, although assumed similar to that exhibited by respiratory epithelia, has not been confirmed for middle ear mucosa as indicated. PRR within the cell cytoplasm, such as NOD-1 and NOD-2 and TLR9 receptors on the endosomes, can also upregulate NF-κB stimulation of type II interferons and proinflammatory and antimicrobial molecules via MyD88-independent and -dependent pathways, respectively. DAI may activate both NF-κB and NF-κB-independent stimulation of type II and type 1 interferons, respectively. POL3 via IRF7 stimulates the MyD88-independent pathway utilized by TLR3, while AIM2, via caspase 1, stimulates formation of IL1 and IL18 formation within the cytoplasm.

The effects of NTHi-induced OM, particularly through activation of TLR signaling pathways, has provided considerable detail of the molecules involved in the signaling cascade within the middle ear mucosal cells. Only recently, however, has the relative importance of the individual molecules in activation of innate immune responses been described in mice, using dysfunctional or gene knockouts for key molecules of innate immunity. These molecules included TLR2, TLR4, MyD88, and TNFα, and the study confirmed their key role in normal immunoregulation of the middle ear innate immune responses including inflammation, mucosal hyperplasia, and cellular recruitment to the middle ear ([@bib85], [@bib84]). (For review see [@bib83].)

It is anticipated that the complexity of signaling cascades resulting from activation of TLRs may be underestimated due to the involvement of common signaling pathways. Furthermore, the timing and importance of individual TLR activations, within the response profile, may also differ. For example, within murine middle ear epithelia, TLR2 is the predominant PRR expressed in response to NTHi ([@bib76]), although TLR4 expression is also upregulated ([@bib84], [@bib90]). However, early TLR4 expression is essential for optimizing the TLR2 upregulation and is necessary for rapid inflammation and clearance of pathogens from the middle ear. Higher levels of TLR2 and TLR4 receptor expression have been observed within the healthy rat middle ear mucosa, compared to the levels observed within either the eustachian tube or nasopharyngeal mucosa ([@bib142]).

The role of signaling molecules in innate responses to pathogens within the middle ear mucosa is further demonstrated by a reduced rate of recovery from NTHi-induced OM in response to deficiencies in TLRs and their downstream signaling molecules, MyD88 and TRIF. Furthermore, MyD88-deficient mice exhibit a prolonged recovery from NTHi-induced OM compared to TRIF-deficient mice, which may indicate a predominant role for MyD88 in recovery from NTHi infection of the middle ear in this species ([@bib54]).

Subsequent activation of NF-κB further down the signaling cascade mediates expression of a variety of molecules in the middle ear mucosa, including inflammatory-related cytokines such as IL-1α, IL-1β, IL-6, IL-10, TNFα, chemokines CCL3 (macrophage inflammatory protein-1a or MIP1a) and CXCL2 (macrophage inflammatory protein-2 or MIP2), and antimicrobials such as β-defensin 2 and mucin genes ([@bib96], [@bib95]). In the rat model, NTHi stimulates stronger activation of the TGF-β pathway than is observed for pneumococcus-infected ears and contributes to the formation of granulation tissue in response to infection ([@bib80]). The roles performed by individual inflammatory mediators in OM pathogenesis have been comprehensively reviewed ([@bib61]).

Investigations using the mouse model have clearly demonstrated that PRR activation results in rapid upregulation of inflammatory cytokine expression in the middle ear, which peaks between 6 and 24 h of original infection. Inflammatory cytokine expression in these mice typically returns toward normal levels within a week. In contrast, the resultant middle ear effusion often lasts considerably longer and genes regulating ion and water movement within middle ear epithelia are mostly downregulated for up to 72 h after infection, with many remaining downregulated a week after infection ([@bib95]). These findings from the mouse model are consistent with the timing of middle ear immune responses to pathogen colonization and OM pathogenesis in humans.

Systemic cytokine profiles in children show that recurrent or chronic OM results in increased serum concentrations of T-helper (Th)-2 cytokines, IL-4 and IL-5, in affected children compared with healthy children. Furthermore, serum IL-6 levels are also increased in children with AOM due to *S. pneumoniae* ([@bib51]). Attempts to utilize the characteristics of proinflammatory cytokine secretion to assist with clinical differentiation of chronic versus acute OM in children have been reported. For example, middle ear effusate (MEE) samples from chronic OME patients show TNFα, IL-1β, and IL-8 in 77--91%, 67--97%, and 92--100% of samples, respectively ([@bib140]). In addition, upregulation of TNFα may also be an important factor in the persistence of OME, whereas IL-8, a PMN (Polymorphonuclear)-related inflammatory cytokine, may impact AOM recurrence or delay recovery ([@bib14]).

Overall, immune responses in otitis-prone children show evidence of reduced capacity to prevent or regulate bacterial colonization at all stages of the immune response, including gene variation in *TNFA-238G*, *TNFA-376G*, *TNFA-863A*, *IL6-174G*, and *IL10-1082A* ([@bib30]). Otitis-prone children exhibit reduced expression of TLR9 and other PRRs, including NOD-1, RIG-1 mRNA in their MEE ([@bib68]), and lower levels of IL-1β, IL-6, and TNFα in nasopharyngeal secretions ([@bib92]). Finally, otitis-prone children also demonstrate reduced proliferation of lymphocytes in adenoidal tissue after inoculation with the NTHi outer membrane protein P6 ([@bib69]), fewer CD4^+^ T and total T cells in adenoidal tissue, and reduced levels of total serum IgG2 ([@bib35]). Together, these reports suggest that dysfunction in both innate and adaptive immune responses within the middle ear may increase host susceptibility to recurrent OM.

Local Immune Response in Middle Ear Mucosa {#s0060}
==========================================

Cellular Response {#s0065}
-----------------

Innate immune responses within the middle ear mucosa occur rapidly and nonspecifically to facilitate dual objectives, otopathogen eradication and stimulation of adaptive immune defenses for the prevention of subsequent infection by the same pathogens.

Although immunocompetent cells are rarely observed in healthy middle ear mucosa, experimental induction of OM in the rat results in a rapid, large increase in granulocytes with moderate increases in T and B lymphocytes, primarily Th (CD4^+^) and IgG^+^ and IgM^+^ B lymphocytes, as well as NK cells ([@bib59]). MEE, adenoid, and peripheral blood samples from children experiencing OME with effusion exhibit a predominance of CD4^+^ memory cells and naïve CD8^+^ cells ([@bib137]).

Proliferation of lymphocytes within the adenoids results in homing to the middle ear; however, inflammation also stimulates increased local proliferation of lymphocytes within the middle ear mucosa itself in a number of animal models, including mouse and rat ([@bib150], [@bib59], [@bib56]). Surprisingly, the number of proliferating B and T lymphocytes observed in rat middle ear mucosa is higher than previously observed in normal lymphatic organs such as the spleen, with dendritic cell, macrophage, and natural killer cell proliferation even higher. In contrast, leukocyte proliferation and recruitment within eustachian tube mucosa is less than observed for the middle ear in a rat AOM model ([@bib59]) and may provide further evidence of the specific localization of the immunocompetent cell proliferation to the middle ear mucosa.

Cellular proliferation is another characteristic feature of experimentally induced OM and has been observed in a variety of animal models. Mucosal epithelial cell hyperplasia and edema is stimulated by inflammatory cytokine release and the resultant increased mucosal thickness reduces the opportunity for pathogen invasion of the epithelial cells through the middle ear mucosa.

The extent of mucosal hyperplasia, in response to otopathogens such as NTHi, is regulated by release of local proinflammatory cytokines, including TNFα, as demonstrated using TNFα knockout mice. These mice exhibit middle ear mucosal thickening, increased leukocyte infiltration, increased macrophage rather than neutrophil recruitment, and persistence of leukocytes within the middle ear mucosae, characterizing OM infection ([@bib29]). Several intracellular signaling pathways are involved in the stimulation of mucosal hyperplasia during OM---three primary groups of distinctly regulated MAPK cascades, including extracellular signal-regulated kinase 1/2 (ERK1/ERK2), p38 MAPK, and JNK ([@bib36]), although MAPK-independent pathways may also be involved.

### Mast Cells {#s0070}

Mast cell presence and degranulation also contribute to the rapid, nonspecific inflammatory responses by mucosal epithelia to bacterial antigens and result in phagocytosis of bacteria and release of proinflammatory cytokines ([@bib106], [@bib25]). More generally, there is evidence to suggest that mast cells may also modulate responses by the adaptive immune system ([@bib38], [@bib133]). Although predominantly examined in vitro, mast cell secretion of biologically active molecules such as histamine, TNFα, and IL-6 may influence the migration, maturation, or differentiation of DC, T cells, and B cells, respectively. (For review, see [@bib38], [@bib37].)

In some animal models, such as in the murine middle ear, mast cells are not essential for early response to bacterial infection; however, their presence optimizes the rapidity and magnitude of the response. These roles have been demonstrated using NTHi inoculation in W/W^v^ mice, which lack mast cells, and it was estimated that up to half the strength of early mucosal inflammatory response to NTHi results from mast cell degranulation ([@bib28], [@bib116]). Importantly, mast cell-independent factors including proinflammatory cytokines TNFα, IL-1β, IL-6, and IL-8 may dominate responses in the longer term ([@bib140]). Reconstitution of the mast cell population in these knockout mice restored the mucosal response, and together these findings support the mast cell role as a cellular sentinel in the normal innate response in the middle ear mucosa. In humans, the presence of increased density of tryptase-positive mast cells within granulation tissue in the middle ear mucosa of patients with chronic OM is associated with poorer postoperative healing and increased risk of OM recurrence ([@bib116]).

### Mucus and Fluid Flow {#s0075}

Bacterial antigens also rapidly stimulate the eustachian tube and middle ear to secrete mucus. The secreted mucus predominantly contains mucin (MUC), a diverse family of highly glycosylated proteins ([@bib66], [@bib93]). In general, MUC1, MUC4, and MUC16 appear to facilitate localized adherence to the cell membrane while MUC2, MUC5AC, MUC5B, and MUC19 help to form a movable mucus layer ([@bib93]). The movable mucus layer then permits mucus protection of epithelial cells from pathogens by provision of a mechanism for removal, via cilia action, through the eustachian tube to the nasopharynx ([@bib31]).

Mucin transcription is frequently upregulated in response to common otopathogens such as *S. pneumoniae* and NTHi via the TLR2/4-MyD88-TAK1 signaling cascade. Furthermore, these otopathogens can act synergistically to upregulate MUC5AC transcription by activation of the mitogen-activated protein kinase kinase 3/6 (MKK3/6 p38) and ERK MAPK pathways ([@bib134]). Human middle ear epithelium expresses many of the known mucin genes, including MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC5B, MUC7, MUC8, MUC9, MUC11, MUC13, MUC15, MUC16, MUC18, MUC19, and MUC20 ([@bib66]). Human middle ear epithelial (HMEEC) cell lines have provided considerable evidence of identification and regulation of intracellular signaling pathways in response to *S. pneumoniae* and NTHi infection and indicate that predominantly MUC5AC is the mucin upregulated ([@bib134], [@bib70], [@bib91], [@bib78]). In contrast, evidence from COM patients suggests that MUC5B upregulation was predominant over MUC5AC and that MUC2, MUC19, and MUC7 were not detected in the MEE ([@bib120]). Recent cell-culture evidence suggests that MUC1 mucin upregulation in A549 airway epithelial cells may help control inflammation during infection with NTHi through suppression of TLR2 signaling and reduced IL-8 production ([@bib74]). These findings suggest a potential anti-inflammatory role for MUC1 mucin in OM pathogenesis.

Mucus production and its viscosity within the middle ear are also influenced by water flow through and between the subepithelial, epithelial, and apical or luminal compartments of the mucosal epithelium. Aquaporins are a family of integral membrane proteins that act as specialized channels to facilitate water passage through cell membranes in a wide variety of organisms including bacteria, animals, and plants. Aquaporins 1, 4, and 5 are expressed in the rat eustachian tube and middle ear epithelium and are localized within the subepithelial fibroblasts, basolateral membranes of the ciliated epithelial cells, and apical surface of the serous glands ([@bib62]), respectively. Murine expression of aquaporins within the eustachian tube showed similar localization of aquaporin proteins 1, 4, and 5 within the mucosal epithelia, with aquaporin 3 ([@bib149]) also localized to the basal membrane of mucosal epithelial cells. Heat-killed NTHi injected into the middle ear resulted in downregulation of the majority of middle ear aquaporin genes in the murine model ([@bib95]); thus NTHi infection within the middle ear may contribute to effusion by this mechanism.

Fluid regulation and ion transport also contribute to water movement through mucosal membranes and may contribute to the transudation of fluid into the middle ear cavity during AOM. Recent studies have reported rapid upregulation of eight key inflammatory cytokines, IL-1α, IL-1β, IL-6, IL-10, MIP-1α, MIP-2, KC (proinflammatory chemokine), and TNFα, within 6--24 h after injection of heat-killed NTHi into the murine middle ear, whereas vascular endothelial growth factor (VEGF) and MAPK8 expression were downregulated ([@bib96], [@bib95]). In contrast, most of the 24 inner ear ion homeostasis genes examined were downregulated during the inflammation, particularly aquaporin and Na^+^, K^+^-ATPase genes, which supports the early transudation of fluid into the middle ear. While the proinflammatory cytokine gene expression returned to normal over the following week, ion homeostasis genes remained downregulated, perhaps in response to the fluid within the middle ear ([@bib96]), which might help to explain why middle ear effusion persists after the infection is cleared.

Fluid movement over mucosal epithelial surfaces is improved by the action of surfactant, which reduces surface tension in liquid--air interfaces such as the respiratory tract and tubotympanum. Lung surfactant protein A (SP-A) and lung surfactant protein D (SP-D) are two large hydrophilic proteins of the collectin family that act to enhance phagocytosis of gram-negative bacteria. Both are expressed within the eustachian tube and middle ear epithelium. SP-A and SP-D expression has been localized to the microvillar epithelial cells in the pig eustachian tube ([@bib115]) and may contribute to the prevention of bacterial ascension to the middle ear. Furthermore, surfactant apoprotein has also been detected in human middle ear effusions ([@bib167]) and children susceptible to recurrent OM show differences in specific SP haplotypes ([@bib122]).

### Antimicrobial Proteins and Peptides {#s0080}

Overlaying the mucosal epithelial cells, mucus also provides an antimicrobial barrier containing molecules such as lysozyme, lactoferrin, and β-defensins, which act independently and together to inhibit bacterial colonization and stimulate adaptive immune responses ([@bib53], [@bib158]). The importance of antimicrobial peptides within the middle ear mucosa to reduce middle ear colonization and invasion has been demonstrated in the chinchilla model. In this model, inoculation with an NTHi mutant, NTHi *sapA*, that exhibits an increased sensitivity to an antimicrobial protein, recombinant chinchilla β-defensin 1 (cBD-1), a human-defensin 3 homolog, resulted in OM disease attenuation and reduced bacterial survival ([@bib100]). Antimicrobial proteins perform both bactericidal and nonbactericidal actions to maintain normal middle ear function. For example, small interfering RNA knockdown of short palate, lung, and nasal epithelium clone 1 (SPLUNC1) in the chinchilla did not alter NTHi survival in the middle ear but demonstrated that expression of SPLUNC1 peptide was essential for maintenance of normal mucociliary clearance and middle ear pressurization ([@bib103]).

### Lysozyme {#s0085}

Lysozyme is a potent antibacterial molecule produced by PMNs and mononuclear inflammatory cells that acts by disruption of bacterial cell membranes to reduce the opportunity for bacterial colonization and invasion of middle ear mucosae. Lysozyme rapidly accumulates within the MEE, within 6 h of experimental NTHi infection. Accumulation of lysozyme occurs approximately 6 h before inflammatory cell influx in the guinea pig model ([@bib65]). Furthermore, MEE concentrations of lysozyme are higher in children with mucoid OM compared to children experiencing serous OM ([@bib46], [@bib94]), and lysozyme secretion was localized to middle ear goblet cells in children ([@bib89]). In contrast, lysozyme was localized to the serous glands and epithelial cells and middle ear mucosa in the chinchilla ([@bib44]). Lysozyme knockout mice (M^−/−^) are more susceptible to pathogen colonization of the middle ear and develop a more severe middle ear inflammatory response after exposure to *S. pneumoniae* 6B infection ([@bib135]), thus supporting the antibacterial role of lysozyme within the middle ear. Furthermore, human lysozyme can act synergistically with β-defensin 2 to reduce *S. pneumoniae* 6B viability by directly killing the invading pathogen ([@bib77]). Clearly, antimicrobial proteins such as lysozyme may act both independently and together to prevent bacterial colonization and maintain normal function of the middle ear.

### Defensins {#s0090}

Defensins are endogenous broad-spectrum antimicrobial peptides considered to be antecedents of the immune response. These peptides are active against a wide variety of bacterial, viral, and fungal pathogens and are an evolutionarily conserved characteristic of the innate immune system ([@bib81]). HMEEC can secrete lysozyme and a range of human β defensin (hBD) molecules, including hBD1, hBD2, and hBD3. Pathogen testing confirms hBD1 has bactericidal activity to *M. catarrhalis* while hBD2 is bactericidal for all three predominant bacterial otopathogens, NTHi, *S. pneumoniae*, and *M. catarrhalis* ([@bib77]). Within the human middle ear, expression of hBD2 and hBD3, but not hBD1, are upregulated in human middle ear cholesteatoma epithelium ([@bib143], [@bib119]). Both hBD1 and hBD2 act primarily against gram-negative bacteria, but hBD2 may also target gram-positive bacteria and hBD3 appears to provide a broad-spectrum killing of multiple pathogenic microbes ([@bib47]).

Similarly, in the murine model, expression of murine β-defensin (mBD) molecules mBD-2, mBD-3, and mBD-4 is increased; however, mBD-1 and mouse α-defensin expression were unchanged in response to injection of endotoxin into the middle ear ([@bib60]). Invading pathogens such as RSV can also suppress cBD-1, a hBD 3 ortholog; upregulation; and peptide secretion, thus resulting in enhanced otopathogen colonization of the middle ear in the chinchilla model ([@bib104]). Furthermore, subsequent intranasal administration of exogenous recombinant cBD-1 reduced the bacterial load of NTHi recovered from airway mucosae ([@bib104]). The relevance of bacterial load is also evidenced from human middle ear cell lines where NTHi induced IL-1α secretion and NTHi components synergistically upregulate epithelial cell secretion of β-defensin ([@bib109]).

Overall, viral suppression of expression of cBD-1, and secretion of its antimicrobial peptide, can increase bacterial colonization in the middle ear and nasopharynx, a key event in failure of pathogen clearance by the middle ear and OM pathogenesis.

### Complement {#s0095}

Complement is also a significant component of early mucosal defense of the middle ear and deficiency in complement proteins has long been associated with impaired opsonization in children experiencing OM ([@bib144]).

The importance of the role of complement in NTHi-induced OM was investigated experimentally by complement depletion induced using cobra venom factor. Complement depletion restored the virulence of two otherwise avirulent NTHi strains (NTHi *siaβ* mutants) that exhibit reduced capacity to sialylate lipopolysaccharide in a murine OM model ([@bib32]).

Mannose binding lectin (MBL) can also facilitate opsonization of bacterial pathogens through specific oligosaccharide binding activation of the complement pathway; however, significant reduction in serum MBL was not observed in a prospective study of children experiencing recurrent OME ([@bib146]).

Further evidence of the role of complement proteins in reducing the risk of OM development is demonstrated by increased binding of complement C3 protein (C3). *Streptococcus pneumoniae* 6A strains that exhibited either low or high C3 binding were examined using a murine model and increased deposition of C3 protein resulted in improved pathogen clearance from the middle ear, through facilitated opsonization of invading otopathogens. Thus, ultimately, the opportunity for bacterial adherence to the mucous epithelial cell layer was reduced, subsequently reducing the risk of OM development ([@bib126]).

### Cytokines {#s0100}

The middle ear and eustachian tube possess an effective innate immune system. Innate immune responses are rapidly induced in response to otopathogens in a nonspecific manner through stimulation of a variety of cell signaling pathways, including local production of inflammatory cytokines and type I interferons ([@bib151]). Investigation of the expression of inflammatory cytokine gene expression in the middle ear has been investigated using a number of animal models, including the AOM murine model induced by *trans*-tympanic injection of *S. pneumoniae*. In this model, AOM mice demonstrated upregulation of IL-1α, IL-1β, IL-2, TNFα, and IL-6, with IL-1α, IL-1β predominant 24 h after administration of the pathogen ([@bib96]). Examination of chronic OM, using a spontaneously induced OM murine model, the C3H/HEJ mouse (defective TLR4 thus mounts an ineffective immune response to gram-negative bacteria), showed further increase of the upregulation of IL-1α, IL-1β, and TNFα but also demonstrated cytokine genes related to tissue remodeling (TNFα, FGF, BMP) and angiogenesis (VEGF) ([@bib96]). Together, these studies emphasize the intricate control and progressive modification of cytokine gene expression during both the initial and chronic inflammatory responses to otopathogens in the middle ear and their potential role in chronic OM pathogenesis. These responses reduce the opportunity for bacterial adherence to the mucosa and activate adaptive immune responses to upregulate acquired immune responses to then further reduce pathogen invasion within the middle ear mucosa.

Acquired Immune Response and the Middle Ear {#s0105}
-------------------------------------------

The middle ear mucosa is proximal to the adenoids and palatine tonsils, which are key components of the regional MALT, or more specifically, the nasal associated lymphoid tissue (NALT) in association with other small structures in the Waldeyer ring in humans. NALT is considered a key immune induction site of the upper airways, where antigens can be directly sampled via microfold (M) cells in the lymphoid follicle-associated epithelium for processing and presentation by APC such as DC to naïve lymphocytes. In addition, within the middle ear mucosa, antigens may be sampled by intra- and subepithelial DC, which then migrate through the draining lymphatic vessels to regional cervical lymph nodes.

Antigen sampling and key immune induction sites may vary between species, and recent focus on improved immune responses to vaccination via inhalation have frequently used murine models. (For review, see [@bib128], [@bib127].) Selective surgical removal of specific tissues comprising the NALT in mice clearly demonstrated that for this species, the cervical lymph nodes performed a greater role in induction of the immune response than did NALT ([@bib128]).

Recently, respiratory M cells or isolated individual antigen sampling cells were identified in the murine airways. These isolated cells function equivalently to M cells within MALT but are located locally within mucosal tissue such as nasal cavity epithelium. CD11C^+^ DC migrate under these cells to receive antigen after intranasal infection. These M cell-like cells may provide a NALT-independent induction pathway for generation of antigen-specific mucosal immune responses ([@bib67]). Furthermore, if present in the middle ear, these cells may result in the induction of a specific antibody response within the middle ear, particularly in patients who have chronic OM where germinal centers can be identified in the middle ear and eustachian tube epithelium ([@bib101]).

### Secretory Immunoglobulin A in the Middle Ear {#s0110}

Acquired immunological defense in the upper respiratory tract, including the middle ear, in brief, is dependent on the formation of secretory immunoglobulin A (S-IgA), which can minimize bacterial adherence and improve bacterial clearance via opsonization and phagocytosis. During the mucosal immune response, B-cell stimulation of S-IgA secretion occurs initially in the induction sites such as MALT, with S-IgA subsequently secreted at effector sites, which often include but are not limited to the site of pathogen colonization.

IgA is regarded as a hallmark for local immune responses at mucosal surfaces ([@bib11]) and early evidence of the middle ear acting as an effector site of the mucosal immune system was the presence of S-IgA in the MEE at a greater concentration than IgG and IgM during antigen-induced inflammation ([@bib114]). Antigen-specific IgA-producing cells have been identified in the inflamed middle ear; however, other immunoglobulin isotypes are also present. In a study of the anti-NTHi P6 antibody profiles in MEE from children who were prone to OM, but undergoing an acute or subacute infection episode due to NTHi, it was demonstrated that 92% of the MEEs were positive for IgG anti-P6 antibody, 78% for IgA, 70% for IgM, and 45% for SIgA. While the level of IgG, IgA, and IgM anti-P6 antibodies correlated well with those observed in serum, SIgA levels did not ([@bib166]). Interestingly, the MEF from patients with AOM has been reported to show higher IgA concentrations compared to blood samples from patients with OME, while IgM and IgG concentrations are less in MEF compared to serum ([@bib139], [@bib168]). Another report indicates that IgG and IgA concentrations within the serum and MEF concentrations are reduced in patients with recurrent OME compared to control patients ([@bib600]). No significant differences have been reported in serum IgA, IgA2, IgG, and IgG2 between children 3--10 years of age, regardless of whether they have OME or not ([@bib27]). To our knowledge, no studies have reported more comprehensive IgA subclass profiles in MEEs or serum within otitis-prone children. Furthermore, a recent report indicates a nonsignificant increase in MEF IgA levels against the pneumococcal IgA-1 protease protein in *S. pneumoniae*-negative/COME-positive children, which may indicate a role in improving the binding of IgA to improve bacterial clearance. This study also reported evidence of a positive correlation between antigen-specific serum and MEE IgG levels for both *M. catarrhalis* and *S. pneumoniae* antibodies, which suggests that the antibody response in the middle ear is derived from both the systemic circulation and local mucosal tissue in the middle ear ([@bib160]).

Another study reported that the IgG:IgA ratio in MEF resembled that observed in serum but that small amounts of SIgA were also detected ([@bib64]).

It is likely that the relationship between the mucosal and systemic responses may change as the infection of the middle ear progresses, as suggested by [@bib148], whereby antibodies to *M. catarrhalis* outer membrane proteins detected in the early phase of middle ear infection may be primarily derived from blood and a more local antibody response, accompanied by increasing levels of SIgA, occurs as the infection progresses. If this is the case, it may explain why children who have a generally lower systemic IgG response to otopathogens are prone to OM ([@bib35], [@bib148], [@bib159], [@bib63]) and that once colonization and infection occurs, it would prove increasingly difficult for the local immune response stimulated to clear the middle ear of microbes. Furthermore, the formation of biofilms and/or intracellular colonization of the middle ear epithelia may then reduce the opportunity for the successful clearance of microbes from the middle ear by a subsequent local immune response.

Unfortunately, it is likely that pathogenesis of OM is more complex than suggested above, since antigen-specific serum IgG or IgA antibody responses following vaccination with a pneumococcal conjugate vaccine are not impaired in otitis-prone children ([@bib107]). Furthermore, children experiencing recurrent AOM can produce adequate IgG, IgG1, and IgG2 responses against pneumococcal polysaccharides induced by either vaccination or natural exposure ([@bib19]). Unfortunately, children with low levels of nasopharyngeal SIgA-specific anti-P6 antibodies are unable to reduce the density of NTHi colonization, irrespective of the load of initial NTHi colonization ([@bib45]), and in these children, the frequency of OM was directly related to the frequency of NTHi colonization. Subsequent studies, however, do support a relationship between the concentration of specific antibody responses following natural exposure to common otopathogens in serum and MEF in children who are prone to recurrent AOM ([@bib8], [@bib132], [@bib146]). Indeed, rapid inactivation and clearance of pathogenic bacteria are observed in children where elevated specific serum antibodies, particularly IgG, are identified ([@bib35]); however, recurrent OM remains a key clinical indicator for identifying children with potential immunodeficiency ([@bib163]).

### Cellular Recruitment and Local Proliferation in the Middle Ear {#s0115}

The concept that local immune responses within the middle ear and eustachian tube, in response to AOM, are the result of a combination of local proliferation of immunocompetent cells as well as being the destination of immunocompetent cells from surrounding NALT has been illustrated by a number of animal models, including rat ([@bib58]), mouse ([@bib85]), and chinchilla ([@bib7]). In these models, the relative paucity of immunocompetent cells within the middle ear mucosa was significantly increased within 24 h of otopathogen administration to the middle ear. In response to immune stimulation, lymphocytes have been reported to enter the middle ear mucosa from a variety of lymphatic sources as determined using chromium-51-labeled lymphocytes in guinea pig ([@bib125]). A subsequent study examined lymphocytes in the MEE of children experiencing either OME or adenoid hypertrophy and reported that the adenoid may be a primary source for T lymphocytes that can home to middle ear mucosa during immune response to antigenic challenge and that the majority of these cells were CD45RO^+^, that is, expressed the memory phenotype ([@bib102]). Furthermore, the hypothesis that local proliferation of lymphocytes occurs within the middle ear mucosa ([@bib150]) has been examined during AOM in the rat model using the DNA precursor bromodeoxyuridine to label proliferating leukocytes. Within the middle ear mucosa, the local proliferation rate ranged between 2% and 9% within immunocyte subsets ([@bib59]).

Lymphocyte subpopulations identified in MEE samples from children with chronic OME are reported to consist predominantly of T cells (CD3^+^) and primarily T-helper (CD4^+^) cells with fewer CD8^+^ cytotoxic T cells ([@bib137]). MEE samples from these children show that the CD4^+^ lymphocytes are primarily memory cells (CD4^+^CD45RO^+^), whereas for CD8^+^ cells, there is a predominance of naïve T cells (CD8^+^CD45RA^+^). Middle ear effusions from these children were also reported to show a higher percentage of CD4^+^ and CD8^+^ cells and a higher CD4^+^/CD8^+^ ratio compared to that observed within their peripheral blood. Differences between lymphocyte profiles between MEE and blood samples further suggest that the lymphocyte profile is locally regulated, yet these patients exhibited the same phase of mucosal response occurring in both ears at the same time ([@bib137]).

### T-cell Regulation and Implication for the Middle Ear {#s0120}

The middle ear mucosa is the primary target for adenoid-derived lymphocytes. Hypertrophic adenoids from children with chronic OME are reported to show increased percentages of CD4^+^ and CD8^+^ T lymphocytes with increased expression of CD127 and CD4^+^ T lymphocytes expressing CD132, both of which indicate increased IL-7R expression. IL-7 secretion facilitates timely proliferation and activation of T and B cells to support the development of an effective immune response within the middle ear ([@bib170]). An earlier study reported that for children with COME, percentages of CD4^+^ and CD8^+^ T cells within the adenoid are decreased ([@bib165]).

Another study reports that within the adenoid there is an increased proportion of CD69^+^ Foxp3^high^ CD25^high^ Treg cells with potent immunosuppressive function. These cells were observed in higher numbers in children who were culture positive for *S. pneumoniae* in their nasopharynx, which may be suggestive of adenoidal Treg cells having a role in delayed clearance or persistence of pneumococcal carriage ([@bib171]). Furthermore, it has been reported that the proportion of Foxp3^+^CD4^+^ CD25^+^T/CD4^+^ T cells in the blood of adults with COME was significantly higher than that observed in acute OME, but also higher than that in normal volunteers, which may indicate a role of Treg immunosuppression in the persistence of middle ear infection ([@bib172]). Alternatively, Treg cells during chronic middle ear effusion may perform a significant role in the homeostatic control of inflammation in tissues frequently exposed to pathogens, not simply by suppression of T cell production in total but by increasing the opportunity for T cells that recognize self-antigens to escape selection in the thymus and thus contribute actively to chronic inflammatory processes.

Immune responses to common otopathogens within the middle ear must be tightly regulated given that mucosal surfaces are delicate, often one cell thick. Active regulation of innate immune response is therefore vital to minimize immune-generated tissue destruction and damage. It has been reported that within the middle ear mucosa, antigen-specific Treg cells can improve suppression of immune-mediated OM by inhibition of IgG and IgM plasma cell precursors while stimulating IgA-forming plasma cells ([@bib157]). Thus, mucosal immunization may significantly reduce induction of immune-mediated damage in the middle ear through reduced risk of reduction of IgG-induced mucosal inflammation and increased antigen-specific S-IgA secretion. Further studies to explore the role of Treg cells in the middle ear are required. However, given observations in the adenoid, Treg cell immunity may be important in the control of inflammatory processes in middle ear infection.

Mucosal Immunization to Prevent Middle Ear Infection {#s0125}
====================================================

The four predominant otopathogens are *S. pneumoniae*, NTHi, *M. catarrhalis*, and RSV, and vaccine strategies to prevent OM should initially be targeted toward these microbes. For *S. pneumoniae*, the vaccine must include the major serotypes responsible for disease. There are a number of pneumococcal vaccines, developed primarily for prevention of invasive pneumococcal disease, currently available ([@bib23], [@bib24], [@bib21], [@bib130]). One of these vaccines, a polysaccharide-conjugated formulation, uses a protein from NTHi (protein D) as the main carrier protein. Conjugate vaccine efficacy against *S. pneumoniae*-induced AOM for vaccine serotypes is in the order of 55%. A prototype of the conjugate vaccine containing protein D as the polysaccharide carrier demonstrated an efficacy against AOM of 35.3% due to NTHi, as well as a 57.6% efficacy against serotypes included in the vaccine ([@bib121]). For OM resulting from *S. pneumoniae* non-vaccine serotypes, little protection has been observed ([@bib130], [@bib121]). Studies using animal models and the mucosal immunization route have demonstrated that immunization was able to significantly enhance clearance of each bacterium from the middle ear when subsequently challenged with live bacteria ([@bib22]). Inclusion of multiple serotypes in an experimental LOS-based vaccine against *M. catarrhalis* elicited humoral and cellular immune protection against most strains within a mouse model ([@bib123]). For humans, the disappointing outcomes of current polysaccharide conjugate vaccines on AOM, despite good systemic antibody responses, may be several: serotype replacement following vaccination by non-vaccine serotypes or other bacterial otopathogens; different causative *S. pneumoniae* serotypes from those that cause invasive disease; suboptimal antibody responses following immunization to some serotypes; and the lack of induction of mucosal immune responses in the middle ear following systemic immunization ([@bib23]). A greater understanding of immune mechanisms in the middle ear will facilitate the development of vaccination strategies for OM, although it is without doubt that a polymicrobial vaccine will be required.

Conclusion {#s0130}
==========

The global impact of OM on both individuals and the health care system has generated considerable research interest in mucosal immunological response of the middle ear. Ascension of commensal bacteria from the nasopharynx via the eustachian tube to the middle ear initiates innate responses within the middle ear mucosa that, through a complex series of signaling cascades, result in either clearance or failure to clear the pathogen from the middle ear. Secretion of SIgA by the middle ear mucosa may provide improved immunoprotection by prevention of pathogen colonization of the middle ear. Although the majority of childhood middle ear infections resolve uneventfully in most children, very young children are at greater risk of pathogen colonization despite upregulation of innate and acquired immune responses by the middle ear. Mucosal vaccination, targeted to the most common otopathogens, may act via enhanced SIgA response within the middle ear mucosa to prevent development of acute and chronic OM in young children. Finally, the role of regulatory T cells in controlling the middle ear immune response to pathogens requires further investigation. Specifically, the role of regulatory T cells as potential moderators of middle ear inflammatory responses post infection may further reduce the risk of development of chronic or recurrent OM.

Dedication {#s0135}
==========
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